Download Files:
Products Details
Product Description
– Fenlean, a natural squamosamide derivative, is a Src tyrosine kinase inhibitor. Fenlean can inhibit over-activated microglia and protect dopaminergic neurons. Fenlean can attenuate neuroinflammation in Parkinson’s disease models[1][2][3].
Web ID
– HY-123506
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C26H27NO6
References
– [1]Tai W, et, al. Inhibition of Src tyrosine kinase activity by squamosamide derivative FLZ attenuates neuroinflammation in both in vivo and in vitro Parkinson’s disease models. Neuropharmacology. 2013 Dec;75:201-12. |[2]Cheng LB, et, al. Squamosamide derivative FLZ protects retinal pigment epithelium cells from oxidative stress through activation of epidermal growth factor receptor (EGFR)-AKT signaling. Int J Mol Sci. 2014 Oct 17;15(10):18762-75. |[3]Ye X, et, al. FLZ inhibited γ-secretase selectively and decreased Aβ mitochondrial production in APP-SH-SY5Y cells. Naunyn Schmiedebergs Arch Pharmacol. 2014 Jan;387(1):75-85.
CAS Number
– 863193-70-8
Molecular Weight
– 449.50
SMILES
– O=C(/C(C1=CC(OC)=CC=C1OC)=C/C2=CC=C(C(OC)=C2)O)NCCC3=CC=C(C=C3)O
Clinical Information
– No Development Reported
Research Area
– Inflammation/Immunology; Neurological Disease
Solubility
– 10 mM in DMSO
Target
– Src
Pathway
– Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
